Healthcare provider profile · identity verified

Laura M Roe, M.D.

Internal Medicine · PEORIA, IL · NPI 1073809695

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	566	159
Amlodipine Besylate	Amlodipine Besylate	402	113
Levothyroxine Sodium	Levothyroxine Sodium	374	104
Lisinopril	Lisinopril	357	107
Losartan Potassium	Losartan Potassium	271	69
Omeprazole	Omeprazole	238	74
Hydrochlorothiazide	Hydrochlorothiazide	202	65
Metoprolol Succinate	Metoprolol Succinate	174	48
Simvastatin	Simvastatin	166	53
Gabapentin	Gabapentin	159	51
Furosemide	Furosemide	152	46
Rosuvastatin Calcium	Rosuvastatin Calcium	130	42
Pravastatin Sodium	Pravastatin Sodium	128	30
Eliquis	Apixaban	116	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	112	25
Albuterol Sulfate Hfa	Albuterol Sulfate	106	36
Clopidogrel	Clopidogrel Bisulfate	105	33
Metformin Hcl	Metformin Hcl	105	39
Montelukast Sodium	Montelukast Sodium	105	31
Tamsulosin Hcl	Tamsulosin Hcl	105	31
Citalopram Hbr	Citalopram Hydrobromide	95	33
Alendronate Sodium	Alendronate Sodium	88	23
Pantoprazole Sodium	Pantoprazole Sodium	87	24
Donepezil Hcl	Donepezil Hcl	86	13
Escitalopram Oxalate	Escitalopram Oxalate	86	22
Potassium Chloride	Potassium Chloride	86	22
Tramadol Hcl	Tramadol Hcl	81	24
Carvedilol	Carvedilol	80	23
Warfarin Sodium	Warfarin Sodium	79	18
Glipizide Er	Glipizide	77	24
Sertraline Hcl	Sertraline Hcl	77	26
Duloxetine Hcl	Duloxetine Hcl	71	18
Oxybutynin Chloride Er	Oxybutynin Chloride	70	17
Fluticasone Propionate	Fluticasone Propionate	69	29
Metoprolol Tartrate	Metoprolol Tartrate	69	24
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	19
Meloxicam	Meloxicam	67	23
Fenofibrate	Fenofibrate	66	20
Buspirone Hcl	Buspirone Hcl	65	20
Alprazolam	Alprazolam	64	18
Zolpidem Tartrate	Zolpidem Tartrate	64	18
Fluoxetine Hcl	Fluoxetine Hcl	56	16
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	53	13
Cephalexin	Cephalexin	51	41
Lorazepam	Lorazepam	51	26
Memantine Hcl	Memantine Hcl	50	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	50	14
Famotidine	Famotidine	49	suppressed
Ondansetron Odt	Ondansetron	49	16
Atenolol	Atenolol	48	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	46	12
Tizanidine Hcl	Tizanidine Hcl	43	21
Trazodone Hcl	Trazodone Hcl	43	18
Allopurinol	Allopurinol	40	13
Clonazepam	Clonazepam	39	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	39	20
Propranolol Hcl	Propranolol Hcl	36	suppressed
Paroxetine Hcl	Paroxetine Hcl	35	suppressed
Prednisone	Prednisone	35	30
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	35	11
Ezetimibe	Ezetimibe	34	12
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Benazepril Hcl	Benazepril Hcl	33	suppressed
Spironolactone	Spironolactone	33	12
Metformin Hcl Er	Metformin Hcl	31	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Ozempic	Semaglutide	29	suppressed
Baclofen	Baclofen	28	13
Bupropion Xl	Bupropion Hcl	28	suppressed
Phenobarbital	Phenobarbital	28	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	28	11
Nabumetone	Nabumetone	26	suppressed
Jardiance	Empagliflozin	25	suppressed
Nystatin	Nystatin	25	19
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	22	suppressed
Carbamazepine	Carbamazepine	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Glipizide	Glipizide	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Hydrocortisone	Hydrocortisone	19	15
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Temazepam	Temazepam	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Lovastatin	Lovastatin	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Finasteride	Finasteride	16	suppressed
Verapamil Sr	Verapamil Hcl	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	13
Rivastigmine	Rivastigmine Tartrate	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Nifedipine Er	Nifedipine	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Breyna	Budesonide/Formoterol Fumarate	12	suppressed
Budesonide Dr	Budesonide	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Topiramate	Topiramate	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Budesonide Ec	Budesonide	11	suppressed
Clindamycin Hcl	Clindamycin Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Ramipril	Ramipril	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error